Aerovate Therapeutics, Inc. (AVTE): Price and Financial Metrics
AVTE Price/Volume Stats
| Current price | $19.89 | 52-week high | $32.42 |
| Prev. close | $21.20 | 52-week low | $9.41 |
| Day low | $19.83 | Volume | 8,102 |
| Day high | $20.72 | Avg. volume | 131,419 |
| 50-day MA | $24.38 | Dividend yield | N/A |
| 200-day MA | $17.99 | Market Cap | 554.14M |
AVTE Stock Price Chart Interactive Chart >
Aerovate Therapeutics, Inc. (AVTE) Company Bio
Aerovate Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on developing drugs that enhance the lives of patients with rare cardiopulmonary disease. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension. The company was incorporated in 2018 and is headquartered in Boston, Massachusetts.
Latest AVTE News From Around the Web
Below are the latest news stories about AEROVATE THERAPEUTICS INC that investors may wish to consider to help them evaluate AVTE as an investment opportunity.
Aerovate Therapeutics Announces Simultaneous Completion of Enrollment in Phase 2b Portion and Enrollment of First Patient into Phase 3 in the IMPAHCT Trial Evaluating AV-101 for the Treatment of Pulmonary Arterial HypertensionTopline Phase 2b data expected in June 2024 More than 120 sites around the world actively recruiting in the Phase 3 portion of the IMPAHCT trial WALTHAM, Mass., Nov. 20, 2023 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of patients with rare cardiopulmonary disease, today announced the Phase 2b portion of the Inhaled iMatinib Pulmonary Arterial Hypertension Clinical Trial |
Aerovate Therapeutics Inc Reports Increased R&D Expenses and Net Loss in Q3AVTE's Third Quarter Financials Show Continued Investment in Clinical Trials |
Aerovate Therapeutics Announces Third Quarter Financial Results and Business HighlightsWALTHAM, Mass., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of patients with rare cardiopulmonary disease, today announced financial results for the quarter ended September 30, 2023, and recent business highlights. Recent Highlights IMPAHCT Global Phase 2b/Phase 3 Clinical Trial on Track for Topline Data in the Second Quarter of 2024. IMPAHCT (Inhaled iMati |
12 Best Micro Cap Stocks To Invest InIn this piece, we will take a look at the 12 best micro cap stocks to invest in. To skip our introduction to micro cap investing, some benefits, and potential risks, you can skip ahead to 5 Best Micro Cap Stocks To Invest In. Depending on who you ask, it can be argued that the […] |
Down More Than 50%: 2 ‘Strong Buy’ Stocks That Are Too Cheap to IgnoreThe stock market is regularly affected by wider macro developments but that only paints part of the picture. While overall market conditions can push any stock down, when you zoom in, you’ll find that every stock writes its own story, with its own reasons for ups and downs, and savvy investors will make sure to do the background research, learning those idiosyncratic reasons, before buying in. Recognizing this, we’ve turned to some of the Wall Street analyst recommendations for pointers on two s |
AVTE Price Returns
| 1-mo | -22.46% |
| 3-mo | 12.50% |
| 6-mo | 107.62% |
| 1-year | 5.35% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -12.11% |
| 2023 | -22.76% |
| 2022 | 148.52% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
Loading social stream, please wait...